Interventions and public health nutrition

Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women

Abstract

Background

Anti-oestrogens such as tamoxifen, decrease the risk of breast cancer but are unsuitable for prevention because of their side-effects. Diet modifications may be a breast cancer prevention strategy. Here, we investigated if a diet addition of flaxseed, which can be converted to the phytoestrogen enterolactone by the gut microbiota, exhibited similar effects as tamoxifen on normal human breast tissue in vivo, with special emphasis on inflammatory mediators implicated in cancer progression.

Subjects

A total of 28 postmenopausal women were included. Thirteen women added 25 g of ground flaxseed per day and 15 were treated with tamoxifen as an adjuvant for early breast cancer for 6 weeks. Microdialysis of normal breast tissue and, as a control, in subcutaneous abdominal fat was performed for sampling of extracellular proteins in vivo before and after exposures.

Results

Enterolactone levels increased significantly after flaxseed. IL-1Ra and IL-1Ra/IL-1β ratio in the breast increased in a similar fashion after the two different treatments. Flaxseed also increased breast specific levels of IL-1RT2, IL-18 and sST2 and an overall increase of MMP-9. These changes correlated significantly with enterolactone levels. Tamoxifen decreased breast tissue levels of IL-8 and IL-18. None of the treatments induced any changes of IL-1β, IL-1RT1, IL-18BP, IL-33, IL-6, IL-6RA, MMP-1, MMP-2 and MMP-3.

Conclusions

We conclude that dietary flaxseed and tamoxifen exert both similar and different effects, as listed above, on normal breast tissue in vivo and that a relatively modest diet change can induce significant effects on the breast microenvironment.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Dong JY, Qin LQ. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat. 2011;125:315–23.

    CAS  PubMed  Google Scholar 

  2. 2.

    Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer. 2006;54:184–201.

    CAS  PubMed  Google Scholar 

  3. 3.

    Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H. Serum enterolactone and risk of breast cancer: a case–control study in eastern Finland. Cancer Epidemiol Biomark Prev. 2001;10:339–44.

    CAS  Google Scholar 

  4. 4.

    Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, et al. Plasma enterolactone and breast cancer incidence by estrogen receptor status. Cancer Epidemiol Biomark Prev. 2004;13:2084–9.

    CAS  Google Scholar 

  5. 5.

    Saarinen NM, Power K, Chen J, Thompson LU. Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int J Cancer. 2006;119:925–31. https://doi.org/10.1002/ijc.21898.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Bergman Jungestrom M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. Clin Cancer Res. 2007;13:1061–7.

    PubMed  Google Scholar 

  7. 7.

    Zaineddin AK, Vrieling A, Buck K, Becker S, Linseisen J, Flesch-Janys D, et al. Serum enterolactone and postmenopausal breast cancer risk by estrogen, progesterone and herceptin 2 receptor status. Int J Cancer. 2012;130:1401–10.

    CAS  PubMed  Google Scholar 

  8. 8.

    Seibold P, Vrieling A, Johnson TS, Buck K, Behrens S, Kaaks R, et al. Enterolactone concentrations and prognosis after postmenopausal breast cancer: assessment of effect modification and meta-analysis. Int J Cancer. 2014;135:923–33.

    CAS  PubMed  Google Scholar 

  9. 9.

    Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215–20.

    PubMed  Google Scholar 

  10. 10.

    Jaskulski S, Jung AY, Behrens S, Johnson T, Kaaks R, Thone K, et al. Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers. Int J Cancer. 2018;143:2698–708. https://doi.org/10.1002/ijc.31647.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    CAS  Google Scholar 

  12. 12.

    Mantovani A, Barajon I, Garlanda C. IL-1 and IL-1 regulatory pathways in cancer progression and therapy. Immunol Rev. 2018;281:57–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Kantono M, Guo B. Inflammasomes and cancer: the dynamic role of the inflammasome in tumor development. Front Immunol. 2017;8:1132.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res. 2007;9:R15.

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Dethlefsen C, Hojfeldt G, Hojman P. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat. 2013;138:657–64.

    CAS  PubMed  Google Scholar 

  16. 16.

    Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15:210.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Li A, Varney ML, Valasek J, Godfrey M, Dave BJ, Singh RK. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis. 2005;8:63–71.

    CAS  PubMed  Google Scholar 

  18. 18.

    Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295:2387–92.

    CAS  PubMed  Google Scholar 

  19. 19.

    Overall CM, Kleifeld O. Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006;6:227–39.

    CAS  PubMed  Google Scholar 

  20. 20.

    Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 2008;68:3405–12.

    CAS  PubMed  Google Scholar 

  21. 21.

    Leifler KS, Svensson S, Abrahamsson A, Bendrik C, Robertson J, Gauldie J, et al. Inflammation induced by MMP-9 enhances tumor regression of experimental breast cancer. J Immunol. 2013;190:4420–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990;1:99–106.

    CAS  PubMed  Google Scholar 

  23. 23.

    Aberg UW, Saarinen N, Abrahamsson A, Nurmi T, Engblom S, Dabrosin C. Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. PLoS ONE 2011;6:e25720.

    PubMed  Google Scholar 

  24. 24.

    Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol. 2009;182:371–8.

    CAS  PubMed  Google Scholar 

  25. 25.

    Dabrosin C. Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res Treat. 2003;80:193–8.

    CAS  PubMed  Google Scholar 

  26. 26.

    Dabrosin C. Increased extracellular local levels of estradiol in normal breast in vivo during the luteal phase of the menstrual cycle. J Endocrinol. 2005;187:103–8.

    CAS  PubMed  Google Scholar 

  27. 27.

    Dabrosin C. Microdialysis—an in vivo technique for studies of growth factors in breast cancer. Front Biosci. 2005;10:1329–35.

    CAS  PubMed  Google Scholar 

  28. 28.

    Dabrosin C. Sex steroid regulation of angiogenesis in breast tissue. Angiogenesis. 2005;8:127–36.

    CAS  PubMed  Google Scholar 

  29. 29.

    Garvin S, Dabrosin C. In vivo measurement of tumor estradiol and vascular endothelial growth factor in breast cancer patients. BMC Cancer. 2008;8:73.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Nilsson UW, Abrahamsson A, Dabrosin C. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo. Clin Cancer Res. 2010;16:3659–69.

    CAS  PubMed  Google Scholar 

  31. 31.

    Abrahamsson A, Dabrosin C. Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo. Oncotarget. 2015;6:22959–69.

    PubMed  PubMed Central  Google Scholar 

  32. 32.

    Uehar M, Arai Y, Watanabe S, Adlercreutz H. Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay. Biofactors. 2000;12:217–25.

    CAS  PubMed  Google Scholar 

  33. 33.

    Adlercreutz H, Wang GJ, Lapcik O, Hampl R, Wahala K, Makela T, et al. Time-resolved fluoroimmunoassay for plasma enterolactone. Anal Biochem. 1998;265:208–15.

    CAS  PubMed  Google Scholar 

  34. 34.

    Abrahamsson A, Morad V, Saarinen NM, Dabrosin C. Estradiol, tamoxifen, and flaxseed alter IL-1beta and IL-1Ra levels in normal human breast tissue in vivo. J Clin Endocrinol Metab. 2012;97:E2044–54.

    CAS  PubMed  Google Scholar 

  35. 35.

    Lindahl G, Saarinen N, Abrahamsson A, Dabrosin C. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res. 2011;71:51–60.

    CAS  PubMed  Google Scholar 

  36. 36.

    Morad V, Abrahamsson A, Kjolhede P, Dabrosin C. Adipokines and vascular endothelial growth factor in normal human breast tissue in vivo—correlations and attenuation by dietary flaxseed. J Mammary Gland Biol Neoplasia. 2016;21:69–76. https://doi.org/10.1007/s10911-016-9352-9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Svensson S, Abrahamsson A, Rodriguez GV, Olsson AK, Jensen L, Cao Y, et al. CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast cancer. Clin Cancer Res. 2015;21:3794–805.

    CAS  PubMed  Google Scholar 

  38. 38.

    Vazquez Rodriguez G, Abrahamsson A, Jensen LD, Dabrosin C. Estradiol promotes breast cancer cell migration via recruitment and activation of neutrophils. Cancer Immunol Res. 2017;5:234–47.

    CAS  PubMed  Google Scholar 

  39. 39.

    Possemiers S, Bolca S, Eeckhaut E, Depypere H, Verstraete W. Metabolism of isoflavones, lignans and prenylflavonoids by intestinal bacteria: producer phenotyping and relation with intestinal community. FEMS Microbiol Ecol. 2007;61:372–83.

    CAS  PubMed  Google Scholar 

  40. 40.

    Landete JM, Arques J, Medina M, Gaya P, de Las Rivas B, Munoz R. Bioactivation of phytoestrogens: intestinal bacteria and health. Crit Rev Food Sci Nutr. 2016;56:1826–43.

    CAS  PubMed  Google Scholar 

  41. 41.

    Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions. Eur J Cancer. 2006;42:751–9.

    CAS  PubMed  Google Scholar 

  42. 42.

    Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA. 2003;100:2645–50.

    CAS  PubMed  Google Scholar 

  43. 43.

    Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 2004;18:161–3.

    CAS  PubMed  Google Scholar 

  44. 44.

    Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family—balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76:25–37.

    CAS  PubMed  Google Scholar 

  45. 45.

    Kaplanski G. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev. 2018;281:138–53.

    CAS  PubMed  Google Scholar 

  46. 46.

    Aguiar MAN, Wanderley CWS, Nobre LMS, Alencar MRM, Saldanha M, Souza AM, et al. Interleukin-18 (IL-18) is equally expressed in inflammatory breast cancer and noninflammatory locally advanced breast cancer: a possible association with chemotherapy response. Asia Pac J Clin Oncol. 2018;14:e138–44.

    PubMed  Google Scholar 

  47. 47.

    Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97:665–75.

    CAS  PubMed  Google Scholar 

  48. 48.

    Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol. 2017;8:475.

    PubMed  PubMed Central  Google Scholar 

  49. 49.

    Xiao P, Wan X, Cui B, Liu Y, Qiu C, Rong J, et al. Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology. 2016;5:e1063772.

    PubMed  Google Scholar 

  50. 50.

    Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125–39.

    CAS  Google Scholar 

  51. 51.

    Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature reviews. Clin Oncol. 2018;15:234–48.

    CAS  Google Scholar 

  52. 52.

    Alfaro C, Sanmamed MF, Rodriguez-Ruiz ME, Teijeira A, Onate C, Gonzalez A, et al. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24–31.

    CAS  PubMed  Google Scholar 

  53. 53.

    Abrahamsson A, Rzepecka A, Romu T, Borga M, Leinhard OD, Lundberg P, et al. Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo. Oncoimmunology. 2016;5:e1229723.

    PubMed  PubMed Central  Google Scholar 

  54. 54.

    Nilsson UW, Garvin S, Dabrosin C. MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat. 2007;102:253–61.

    CAS  PubMed  Google Scholar 

  55. 55.

    Abrahamsson A, Rzepecka A, Dabrosin C. Equal pro-inflammatory profiles of CCLs, CXCLs, and matrix metalloproteinases in the extracellular microenvironment in vivo in human dense breast tissue and breast cancer. Front Immunol. 2017;8:1994.

    PubMed  Google Scholar 

  56. 56.

    Zhu Y, Kawaguchi K, Kiyama R. Differential and directional estrogenic signaling pathways induced by enterolignans and their precursors. PLoS ONE 2017;12:e0171390.

    PubMed  PubMed Central  Google Scholar 

  57. 57.

    Mason JK, Thompson LU. Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? Appl Physiol Nutr Metab. 2014;39:663–78.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank RN Ann-Christine N Andersson at Linköping University Hospital for providing excellent assistance in recruiting the subjects.

Funding

This work was supported by grants to CD from the Swedish Cancer Society (2015/309), the Swedish Research Council (2013–2457), and ALF of Linköping University Hospital.

Author contributions

All authors collaborated on the study conception, study design, and data interpretation. CD and GL recruited the patients. CD performed all microdialysis experiments. AA and GL carried out sample preparation and Luminex and EIA analyses. All authors performed data analysis and drafted the manuscript. All authors read and approved the final version of the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Charlotta Dabrosin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lindahl, G., Abrahamsson, A. & Dabrosin, C. Dietary flaxseed and tamoxifen affect the inflammatory microenvironment in vivo in normal human breast tissue of postmenopausal women. Eur J Clin Nutr 73, 1250–1259 (2019). https://doi.org/10.1038/s41430-019-0396-y

Download citation

Further reading